Group 1 - The 91st National Pharmaceutical Trade Fair was held in Nanjing from November 19-21, covering over 170,000 square meters with more than 8,200 exhibition booths and over 4,000 domestic and international companies participating [1] - The event featured over 70 forums and activities, with more than 550 industry experts and scholars discussing hot topics and future trends in the pharmaceutical industry [1] - Hunan Hansen Pharmaceutical Co., Ltd., a leading company in Hunan's pharmaceutical sector, showcased its products at the Hunan exhibition area, aiming to promote high-quality development in the industry [1] Group 2 - During the Nanjing Pharmaceutical Trade Fair, Hansen Pharmaceutical's core product, Hansen Si Mo Tang Oral Liquid, was awarded a spot on the "2024-2025 Annual Family Essential Medicine Brand" list due to its excellent efficacy and market reputation [2] - Hansen Pharmaceutical adheres to the corporate value of "treating consumers well and continuously providing good products," aiming to contribute more to the health of the Chinese population [2] - The Si Mo Tang Oral Liquid is a compound traditional Chinese medicine for gastrointestinal motility, included in the national medical insurance catalog and recognized as a protected traditional Chinese medicine product [2]

Core Viewpoint - Hansen Pharmaceutical (002412.SZ) is currently in the process of scaling up the research for its new traditional Chinese medicine product, Cangrong Granules, which is in the stage of pilot testing [1] Group 1 - The company is focusing on research and development in the field of traditional Chinese medicine [1] - Cangrong Granules is a new drug under development by the company [1] - The current phase of research involves pilot testing for process scaling [1]

Group 1 - The company, Hansen Pharmaceutical, reported a total of 23,941 shareholders as of October 31, 2025, including those in credit accounts [2]

Core Viewpoint - The company has received a renewed Drug Production License from the Hunan Provincial Drug Administration, ensuring its continued operations until November 6, 2030 [1]. Group 1: License Information - The new Drug Production License is valid until November 6, 2030, with the license number 湘20150132 [1]. - The company is authorized to produce a variety of pharmaceutical forms, including large volume injections, small volume injections, tablets, hard capsules, granules, syrups, tinctures, and traditional Chinese medicine preparations [1]. Group 2: Company Impact - The renewal of the Drug Production License is a routine procedure due to the expiration of the previous license, and it does not have a significant impact on the company's performance [1].

Core Viewpoint - The company has received a renewed drug production license from the Hunan Provincial Drug Administration, which is valid until November 6, 2030 [2] Group 1 - The company is Hunan Hansen Pharmaceutical Co., Ltd. [2] - The announcement was made on the evening of November 17 [2] - The renewed drug production license signifies compliance with regulatory standards [2]

Core Viewpoint - Hansen Pharmaceutical (002412.SZ) has received a renewed Drug Production License from the Hunan Provincial Drug Administration, ensuring the company's normal production operations until November 6, 2030, with no significant impact on its performance [1] Group 1 - The renewed Drug Production License is valid until November 6, 2030 [1] - The renewal was prompted by the impending expiration of the original license [1] - The acquisition of the new license guarantees the company's ongoing production and operations [1]

Core Points - Company obtained a new drug production license from Hunan Provincial Drug Administration, ensuring continued operations until November 6, 2030 [1] - The new license covers a wide range of products including large volume injections, small volume injections, tablets, hard capsules, granules, syrups, tinctures, mixtures, pills, and second-class psychotropic drugs [1] - The renewal of the license is based on the expiration of the previous one and does not have a significant impact on the company's performance [1]

证券代码：002412 证券简称：汉森制药 公告编号：2025-029 湖南汉森制药股份有限公司 关于取得换发《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 湖南汉森制药股份有限公司（以下简称"公司"）近日收到湖南省药品监督管理 局换发的《药品生产许可证》，换发后的《药品生产许可证》的有效期至 2030 年 11 月 06 日，现将有关情况公告如下： 一、新的《药品生产许可证》基本信息 企业名称：湖南汉森制药股份有限公司 法定代表人：刘正清 企业负责人：刘正清 质量负责人：刘爱华 有效期至：2030 年 11 月 06 日 生产地址和生产范围：益阳市赫山区银城大道 2688 号：大容量注射剂、小容量 注射剂、片剂、硬胶囊剂、颗粒剂、糖浆剂、酊剂、合剂、丸剂（蜜丸、水蜜丸、水 丸）、煎膏剂（含中药前处理及提取）、第二类精神药品（氢溴酸右美沙芬颗粒）*** 二、对公司影响及风险提示 许可证编号：湘 20150132 社会信用代码：91430900MA4L101B51 分类码：Ahz 注册地址：益阳市赫山区银城大道 2688 号 本次换发《 ...

Core Viewpoint - Hansen Pharmaceutical has a range of products for treating colds, including Ganmao Qingre Granules, Baibei Yilung Capsules, Compound Acetaminophen and Amantadine Tablets, and Huoxiang Zhengqi Liquid [2] Company Summary - Hansen Pharmaceutical, including its wholly-owned subsidiaries, offers various cold treatment products [2]

Meeting Overview - The first extraordinary general meeting of shareholders for Hunan Hansen Pharmaceutical Co., Ltd. was held on November 13, 2025, combining on-site voting and online voting [4][5][6] - A total of 102 shareholders and their authorized representatives attended the meeting, representing 221,226,929 shares with voting rights, accounting for 43.9640% of the total voting shares [7] Resolutions Passed - The meeting approved several proposals, including amendments to the company's articles of association and various management systems [10] - Specific proposals that received approval include revisions to the rules for shareholder meetings, board meetings, independent director work systems, related party transaction management, external guarantee management, external investment management, dividend management, and fundraising usage management [10] Legal Compliance - The meeting's procedures, including the qualifications of the conveners and attendees, voting procedures, and results, were confirmed to be in compliance with the Company Law and other relevant regulations [12] Election of Employee Representative Director - The fourth second employee representative meeting elected Ms. Hu Qiong as the employee representative director for the sixth board of directors, with her term lasting until the board's term ends [13] - Ms. Hu Qiong's election complies with regulations regarding the composition of the board, ensuring that the number of employee representatives does not exceed half of the total board members [13]